Answers are grounded in this paper and cite their sources.
We estimated the health and economic impact of adult pneumococcal vaccination strategies in Japan, comparing the adult-specific PCV21 (aPCV21) to PCV20. A published Markov model simulated the epidemiology of pneumococcal disease in Japanese adults aged ≥ 65 years over a lifetime horizon using single- and multi-cohort analyses. Outcomes included cases of invasive pneumococcal disease (IPD), non-bacteremic pneumococcal pneumonia (NBPP), disease-related deaths, and direct and indirect costs (2023 Japanese yen [¥]). The base case evaluated vaccination at age 65, while scenario analyses assessed expanded age-based (≥65) vaccination, coverage rates, duration of protection, and indirect protection. Compared to PCV20, aPCV21 prevented 35% more IPD outcomes (cases and deaths) and 33% more NBPP outcomes in the base case. Combined direct and indirect disease/death-related cost savings versus no vaccination increased from ¥3,983 million with PCV20 to ¥5,299 million with aPCV21. Expanding age-based vaccination from adults aged 65 to ≥65 years, prevented an additional 12% points of IPD outcomes and 6% points of NBPP outcomes. Across all scenario analyses, aPCV21 prevented ≥ 25% more cases and costs compared to PCV20. Based on scenario analyses, the use of aPCV21 in Japanese adults provides substantial health and economic benefits compared to PCV20.
No takes yet. Share an insight, caveat, or question.
Mueller et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: